NASDAQ:NMRA Neumora Therapeutics (NMRA) Stock Price, News & Analysis $1.62 -0.02 (-1.22%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$1.64 +0.02 (+1.23%) As of 08/22/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Neumora Therapeutics Stock (NASDAQ:NMRA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Neumora Therapeutics alerts:Sign Up Key Stats Today's Range$1.61▼$1.7050-Day Range$0.73▼$2.3552-Week Range$0.61▼$17.19Volume338,797 shsAverage Volume1.13 million shsMarket Capitalization$262.36 millionP/E RatioN/ADividend YieldN/APrice Target$7.14Consensus RatingHold Company Overview Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts. Read More Neumora Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreNMRA MarketRank™: Neumora Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 589th out of 937 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus RatingNeumora Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.22, and is based on 3 buy ratings, 5 hold ratings, and 1 sell rating.Amount of Analyst CoverageNeumora Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Neumora Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Neumora Therapeutics are expected to grow in the coming year, from ($1.61) to ($1.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neumora Therapeutics is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Neumora Therapeutics is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeumora Therapeutics has a P/B Ratio of 1.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Neumora Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted10.97% of the float of Neumora Therapeutics has been sold short.Short Interest Ratio / Days to CoverNeumora Therapeutics has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Neumora Therapeutics has recently decreased by 20.71%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeumora Therapeutics does not currently pay a dividend.Dividend GrowthNeumora Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.97% of the float of Neumora Therapeutics has been sold short.Short Interest Ratio / Days to CoverNeumora Therapeutics has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Neumora Therapeutics has recently decreased by 20.71%, indicating that investor sentiment is improving significantly. News and Social Media1.4 / 5News Sentiment0.45 News SentimentNeumora Therapeutics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Neumora Therapeutics this week, compared to 9 articles on an average week.Search InterestOnly 2 people have searched for NMRA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Neumora Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders26.80% of the stock of Neumora Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions47.65% of the stock of Neumora Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Neumora Therapeutics' insider trading history. Receive NMRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neumora Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NMRA Stock News HeadlinesNeumora Therapeutics Initiates Phase 1 Study for Schizophrenia Drug NMRA-861August 20, 2025 | msn.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $7.14 Average PT from BrokeragesAugust 18, 2025 | americanbankingnews.comWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was projected. According to Porter Stansberry, this is panic-level borrowing… and a clear sign we’re nearing America’s financial breaking point. In his latest emergency briefing, Porter outlines why the cracks in our system are widening fast—and how Trump’s policies may be accelerating the collapse. More importantly, he reveals three moves you can make now to protect and potentially grow your wealth before the levee breaks.August 24 at 2:00 AM | Porter & Company (Ad)Neumora Therapeutics, Inc.: Promising Potential in Obesity Therapeutics with NMRA-215August 7, 2025 | tipranks.comNeumora outlines six upcoming clinical catalysts and prioritizes obesity program with NMRA-215August 7, 2025 | msn.comNeumora Therapeutics, Inc. (NMRA) Q2 2025 Earnings Call TranscriptAugust 7, 2025 | seekingalpha.comNeumora Therapeutics Reports Q2 2025 Financial ResultsAugust 7, 2025 | tipranks.comNeumora Therapeutics reports Q2 EPS (33c), consensus (37c)August 6, 2025 | msn.comSee More Headlines NMRA Stock Analysis - Frequently Asked Questions How have NMRA shares performed this year? Neumora Therapeutics' stock was trading at $10.60 at the beginning of the year. Since then, NMRA shares have decreased by 84.7% and is now trading at $1.62. How were Neumora Therapeutics' earnings last quarter? Neumora Therapeutics, Inc. (NASDAQ:NMRA) posted its quarterly earnings results on Wednesday, August, 6th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.05. Read the conference call transcript. When did Neumora Therapeutics IPO? Neumora Therapeutics (NMRA) raised $250 million in an IPO on Friday, September 15th 2023. The company issued 14,710,000 shares at $17.00 per share. Who are Neumora Therapeutics' major shareholders? Top institutional shareholders of Neumora Therapeutics include Geode Capital Management LLC (0.57%), AlphaCore Capital LLC (0.21%), Cerity Partners LLC (0.20%) and Federated Hermes Inc. (0.19%). Insiders that own company stock include Amgen Inc, Arch Venture Partners Xii, Llc, Kristina Burow, Robert A Lenz, Joshua Pinto and Michael Lee Milligan. View institutional ownership trends. How do I buy shares of Neumora Therapeutics? Shares of NMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Neumora Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neumora Therapeutics investors own include Grayscale Ethereum Trust (ETH) (ETHE), Vale (VALE), Paycom Software (PAYC), Clean Energy Fuels (CLNE), Centrus Energy (LEU), uniQure (QURE) and ThredUp (TDUP). Company Calendar Last Earnings8/06/2025Today8/24/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NMRA CIK1885522 Webneumoratx.com Phone857-760-0900FaxN/AEmployees108Year FoundedN/APrice Target and Rating Average Price Target for Neumora Therapeutics$7.14 High Price Target$18.00 Low Price Target$1.00 Potential Upside/Downside+340.9%Consensus RatingHold Rating Score (0-4)2.22 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($1.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$243.79 million Net MarginsN/A Pretax MarginN/A Return on Equity-98.95% Return on Assets-87.68% Debt Debt-to-Equity Ratio0.11 Current Ratio10.54 Quick Ratio10.54 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.13 per share Price / Book1.43Miscellaneous Outstanding Shares161,950,000Free Float118,544,000Market Cap$262.36 million OptionableOptionable Beta2.91 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:NMRA) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neumora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neumora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.